Clinical Trial Update: Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer [Phase 2, Phase 3]

View source ↗

Summary

A completed Phase 2/3 study evaluating 18F-DCFPyL PET/CT imaging in prostate cancer; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• 18F-DCFPyL (DCFPyL radiotracer for PSMA imaging)

Snippet

Sponsor: Progenics Pharmaceuticals, Inc. | Conditions: Prostate Cancer | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2021-08-09